First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer Clinical Trial

Official title:

A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01337154
• Other study ID #: TAMI-P2-NSCLC-01
• Status: Terminated
• Phase: Phase 2
• First received: April 15, 2011
• Last updated: June 27, 2013
• Start date: April 2011
• Est. completion date: June 2013

Study information

• Verified date: June 2013
• Source: CytRx
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationMexico: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to determine the progression-free survival and objective response rate in subjects with either stage IIIB with pleural effusion NSCLC or stage IV NSCLC who are treated with up to six cycles of paclitaxel plus carboplatin and either tamibarotene or placebo. Subjects will be randomly assigned to receive tamibarotene, 6 mg/m2, divided as twice daily orally, or an equal number of matching placebo tablets, starting 1 week before chemotherapy and continuing through all 6 cycles and beyond. Subjects will be assessed for response on Day 50, Day 113, then every other month using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 140
• Est. completion date: June 2013
• Est. primary completion date: June 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects must be at least 18 years of age

• Subjects must have pathological findings consistent with primary non-small cell lung cancer of any histology.

• Subjects must have either stage IIIB with pleural effusion or IV NSCLC with radiographically measurable disease (RECIST 1.1 criteria). Women non-smokers with stage IV NSCLC should be screened for EGFR mutation and if positive be excluded from the study and placed on an EGFR kinase inhibitor.

• Subjects must have an ECOG Performance Status =2.

• If corticosteroids are required for controlling cerebral edema, subjects must be on a stable dose for at least 1 week.

• Subjects must have recovered from any toxicity of prior therapies.

• Subjects must be at least 4 weeks removed from surgery or radiation therapy.

• Subjects must have a life expectancy of at least 12 weeks.

• Subjects must have adequate bone marrow function (defined as an absolute neutrophil count of =1500 cells/mm3 and platelet count =100,000 cells/mm3), liver function with total bilirubin =2.0 mg/dL, and serum creatinine =1.5 x institutional ULN.

• Subjects must be able to understand and be willing to sign a written informed consent document.

• Tamibarotene, as with all retinoids, is teratogenic. Therefore, female subjects of childbearing potential must agree to use 2 effective methods of contraception (hormonal, barrier method of birth control, or abstinence) and sexually-active male subjects must agree to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) while participating in this study and for six months afterwards. Women of childbearing potential must have a negative pregnancy test =1 week prior to registration.

• Subjects must be able to swallow tablets.

• If available, tumor specimens must be submitted for immunohistochemistry analyses with their pathology reports.

Exclusion Criteria:

• Subjects who have received or are currently receiving chemotherapy or antibody therapy, or are enrolled in another treatment clinical trial.

• Subjects with a coagulopathy or bleeding disorder.

• Clinically evident congestive heart failure >class II of the New York Heart Association (NYHA) guidelines.

• Serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.

• History or signs of active coronary artery disease with or without angina pectoris (i.e. myocardial infarction with 6 months prior to enrollment, uncontrolled angina, electrocardiographic evidence of acute ischemia).

• Subjects who have a serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol or may not be able to comply with the safety monitoring requirements of the study.

• HIV-positive subjects; however, subjects will not be routinely screened for HIV.

• Subjects who are allergic to any of the intended chemotherapies.

• Female subjects who are pregnant or breast-feeding.

• Active, clinically significant serious infection requiring treatment with antibiotics, antivirals, or antifungals.

• Subjects with peripheral neuropathy =grade 2

• Prior systemic treatment for locally advanced or metastatic disease (exception below): Prior adjuvant chemotherapy for Stage I-III or combined modality chemotherapy-radiation for locally advanced disease allowed if completed >12 months prior to randomization.

• Subjects with brain metastases are only eligible if treated and neurologically stable with no ongoing requirement for corticosteroids, e.g., dexamethasone, for at least 2 weeks.

• Subjects with hypertriglyceridemia (>1000 mg/dL).

• Subjects with elevated liver function tests if AST is =2.5x the institutional or central laboratory's upper limit of normal for subjects without liver metastases, or >5x the institutional or central laboratory's upper limit of normal for subjects with liver metastases.

• Subjects with HbA1c =8.0.

• Subjects taking vitamin A either as a supplement or as part of a multivitamin unless there has been at least a 2 week washout.

• Subjects using concomitant medications that are known inducers or inhibitors of CYP3A4 up to 14 days before Cycle 1 Day 1 (pimozide, diltiazem, erythromycin, clarithromycin, and quinidine, and amiodarone) should be excluded from the study.

• Subjects whose tumors cannot be adequately measured per RECIST 1.1.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Pleural Effusion
• Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion
• Stage IV Non-small Cell Lung Cancer

Intervention

Drug:
• Tamibarotene
Tablet, 6 mg/m2, oral, divided into twice a day dosing.
• Placebo
Tablets, orally, daily

Locations

Country	Name	City	State
Bulgaria	Department of Medical Oncology, Specialized Hospital for Active Treatment of Oncological Diseases	Sofia
Bulgaria	Medical Oncology Clinic, Multiprofile Hospital for Active Treatment	Varna
Bulgaria	Department of Medical Oncology, Complex Oncology Center	Veliko Tarnovo
India	M S Patel Cancer Centre, Shree Krishna Hospital	Anand	Gujarat
India	Dr. Kamakshi Memorial Hospital	Chennai	Pallikaranai
India	G Kuppuswamy Naidu Memorial Hospital, Valvadi Narayanaswamy Cancer Centre	Coimbatore	Pappanaickenpalayam
India	NIZAM's Institute of Medical Sciences	Hyderabad	Andhra Pradesh
India	Orchid Nursing Home	Kolkata	West Bengal
India	Curie Manavata Cancer Centre	Nashik	Maharashtra
India	Shatabdi Super Speciality Hospital	Nashik	Maharashtra
India	Noble Hospital	Pune	Maharashtra
Mexico	Instituto Nacional de Cancerologia	Mexico City
Russian Federation	State Medical Institution: Arkhangelsk Regional Clinical Oncology Center	Arkhangelsk
Russian Federation	State Therapeutical and Prophylatic Institution: Chelyabinsk Regional Clinical Oncology Center	Chelyabinsk
Russian Federation	State Medical Instituion Kursk Regional Oncology Center	Kursk
Russian Federation	Non-State Medical Institution: Central Clinical Hospital #2	Moscow
Russian Federation	St. Petersburg State Healthcare Institution: City Clinical Oncology Center	Saint-Pertersburg
Ukraine	Public Institution: Dnipropetrovsk City Multispeciality Clinical Hospital #4	Dnipropetrovsk
Ukraine	Public Clinical Treatment and Prophylaxis Instituion: Donetsk Regional Antitumor Center	Donetsk
Ukraine	Ivano-Frankivsk Regional Oncology Center	Ivano-Frankivsk
Ukraine	Public Healthcare Instituion: Kharkiv Regional Clinical Oncology Center	Kharkiv
Ukraine	Kyiv City Clinical Oncology Center	Kyiv
Ukraine	Zakarpattia Regional Clinical Oncology Center	Uzhhorod
United States	Hackensack University Medical Center	Hackensack	New Jersey
United States	Kansas City Cancer Center	Kansas City	Kansas
United States	Desert Hematology Oncology Medical Group, Inc.	Rancho Mirage	California

Sponsors (1)

Lead Sponsor	Collaborator
CytRx

Countries where clinical trial is conducted

United States,  Bulgaria,  India,  Mexico,  Russian Federation,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival	Progression-free survival (PFS) is defined as the time from enrollment (i.e., assignment of subject ID number) to first documentation of objective tumor progression or to death due to any cause in the absence of previous documentation of objective tumor progression.	Within 18 months of study start.	No
Secondary	Objective response rate	Objective tumor response will be evaluated using the RECIST 1.1 criteria.	Within 18 months of study start.	No
Secondary	Overall survival		Within 24 months of study start.	No
Secondary	Assessment of quality of life	EORTC QLQ-C30 version 3.	Within 24 months of study start.	No